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Suboptimaladherencewithpreventivemedicationiscommonandoftenunrecognisedasacauseofpoorasthmacontrol.Anumber
of risk factors for nonadherence have emerged from well-conducted studies. Unfortunately, patient report a physician’s estimation
of adherence and knowledge of these risk factors may not assist in determining whether non-adherence is a signiﬁcant factor.
Electronic monitoring devices are likely to be more frequently used to remind patients to take medication, as a strategy to motivate
patients to maintain adherence, and a tool to evaluate adherence in subjects with poor disease control. The aim of this paper is
to review non-adherence with preventive medication in childhood asthma, its impact on asthma control, methods of evaluating
non-adherence, risk factors for suboptimal adherence, and strategies to enhance adherence.
1.Introduction
The aim of this paper is to review non-adherence with
preventive medication in childhood asthma and its impact
on asthma control. Methods of evaluating non-adherence
and risk factors for sub-optimal adherence will be reviewed.
Finally, the latest evidence for strategies to enhance adher-
ence will be summarised.
2. Compliance, Adherence, and Concordance
“Compliance” describes the degree to which a patient takes
a medication as it has been prescribed [1]. Compliance
has largely been replaced by the term “adherence,” which
has fewer negative connotations [1]. It has been argued
that both terms reﬂect a paternalistic model of care rather
than a partnership. However, the alternative “concordance”,
which has been coined to reﬂect a therapeutic decision that
incorporates the common goals of the physician and patient
[1], has not been widely accepted.
3. Management of Asthma and
PreventiveMedication
Preventive medication is the corner stone of treatment for
children with frequent intermittent or persistent asthma [2].
Preventive medication is taken on regular basis and has been
shown to decrease inﬂammation within the lung and to
improve disease outcomes [3].
4. Importance of Adherence with
PreventiveMedication
Non-adherence takes many forms, and the extent to which
a patient is adherent with diﬀerent asthma-related tasks
may vary [4]. Patients may fail to attend appointments,
ﬁll prescriptions, miss doses of medication, or fail to use
their inhalation device correctly. The incorrect use of an
asthma device may be accidental (reﬂecting competence) or
deliberate (contrivance) [5].
The impact of non-adherence depends upon the severity
of the condition and the eﬀectiveness of the treatment. Non-
adherence is not necessarily inappropriate, particularly if
the treatment is ineﬀective or harmful, so-called “intelligent
non-adherence” [6]. The consequence of non-adherence
with medication may also be dependent upon the pattern
of non-adherence and pharmacological characteristics of the
medication [7]. Sub-optimal adherence has been shown to
result in poor disease control [8–10], an increased risk of
hospital admission [11, 12], and asthma-related mortality
[13–15]. If non-adherence is undetected, the physician may2 Pulmonary Medicine
unnecessarily increase the dose of medication or add an
additional treatment, increasing the cost and complexity
of the regimen [16]. It has been estimated that non-
adherence costs the US healthcare system $300 billion each
year [17]. Undetected non-adherence is also important in




Adherence may be measured by collecting data from the
child or parent (direct questioning, questionnaires, and
diaries), evaluating the amount of medication that has
been used (counting returned pills, weighing canisters),
reviewing pharmacy records, electronic monitoring devices
(incorporatedintothepillbottleorpressurisedmetereddose
inhaler), or drug assays (serum or urine drugs levels) [18].
Electronic monitoring devices (EMDs) have been pro-
posed as the Gold standard for measuring adherence [19].
EMDs record a time stamp which can be downloaded and
compared with the prescribed regimen. Using these devices,
it was discovered that some participants in a clinical trial
were discharging large amounts of medication just prior to
reviews, a process referred to as “dumping” [20]. EMDs do
have limitations, most importantly they are expensive, some
devices have been prone to electrical malfunction [18], and
monitoring may itself alter the patients’ behavior [18].
Compared with EMDs, parental report [21], question-
naires [22], diaries [8, 12, 23, 24], canister weights [21,
22, 25–27], and pill counts [28]h a v ea l lb e e nf o u n dt o
overestimateadherence.Evenwhenparentswereaskedabout
their child’s adherence using a nonjudgemental manner,
prefaced by a normalising statement, the level of reported
adherence did not accurately reﬂect data from an EMD
[29]. Patients typically want their actions to be seen to
be appropriate and responsible, a behaviour referred to as
“social desirability” [30]. This strong social convention may
result in seemingly honest people providing exaggerated
reports of medication usage.
Healthcare professionals have been shown to be poor
judges of adherence, identifying non-adherence no better
than would be predicted by chance alone [29, 31–33].
The inability to predict adherence has been shown to be
independent of seniority [34], professional stream (doctors
versus nurses) [31], or how long the physician has known
the patient [33].
6. Adherence RatesinClinicalStudies
Studies that have used EMDs to evaluate adherence with
preventive asthma medication have reported average adher-
ence rates of 50% to 77% [8, 12, 21, 24, 29, 35]. Even
though these ﬁgures are low, they are likely to be higher
than adherence within the general population as the most
nonadherent patients do not normally enroll in trials [36]
and simply being in a trial has been associated with increased
adherence [37].
7. Models of Adherence and Behaviour
Models of adherence provide a framework for conceptual-
ising adherence and have been the basis for recommended
strategies to manage non-adherence in many review articles.
The most commonly cited is the Health Beliefs Model.
According to the Health Beliefs Model, adherence is
determined after a patient balances the costs of treatment
(e.g., ﬁnancial costs, and real and feared side eﬀects) and
threats posed by the health condition against the perceived
beneﬁts of treatment [4].
The Ecological Model takes into account contextual fac-
tors relating to the family (conﬂict, poverty, and education),
social supports, stressors, and cultural factors. It reminds us
that,forsomefamilieshealthmaynotbetheﬁrstpriority[4].
Otherfactorsmaybemorepressing,including homelessness,
substance abuse, and emotional disturbance [38]. The
Ecological Model also takes into account individual factors,
such as their beliefs, skills, motivation for change, and self-
eﬃcacy [4]. Individual factors also include developmental
factors, for example a child’s understanding of causality [39].
Evidencesuggeststhatpeopledonotnecessarilymentally
balance the pros and cons of a given decision. Rather, people
typically make decisions instinctively, unconsciously, and are
strongly inﬂuenced by their emotions and prejudices [40].
8. Risk Factors andImprovingAdherence
8.1. Sex and Age. Studies examining adherence in the
paediatric population [41], including studies using EMDs,
[21, 42] have found no relationship between adherence and
gender. The available data indicates that adherence generally
falls with increasing age [21, 42–44]. The age at which
parents allow children to assume responsibility for taking
their own medication may reﬂect the parents’ ability to
supervise the child, not only the child’s maturity, and this
may result in unfounded conﬁdence in their ability [45].
Parents and children may not be aware of the limits of
theirresponsibilities. Whentheparentandtheirchildbelieve
the other is primarily responsible for remembering to take
medication adherence is lower [46].
8.2. Disease Severity. Patients with frequent symptoms are
not necessarily prompted to take their preventive medica-
tion. Observational studies have revealed that adherence is
lower in those subjects with increased symptoms [35, 42, 44,
47].Non-adherenceshouldalwaysbesuspectedinthosewith
poorly controlled asthma.
8.3. Parent-Child Relationship, Parental Psychopathology, and
Children’s Behaviour. Young children are dependent upon
their parents, and, thus, their domestic environment is
critical in their disease management [48]. Adolescents report
that reminders from parents to take medication are helpful
[49, 50], even if they ﬁnd them annoying [50]. Higher levels
of adherence are reported by adolescents who described
their parents as supportive and lower when their parents are
described as overly anxious or controlling [51].Pulmonary Medicine 3
It is likely that a bidirectional relationship exists between
parents’ psychological function and their child’s asthma con-
trol [52]. Children whose parents had poorer mental health
scores were reported to experience more asthma symptoms,
[53] exacerbations [53], higher rates of health care use [53],
and reduced adherence [54]. A meta-analysis of 26 studies
found that children with asthma, when compared with con-
trols,havemorebehaviouraldiﬃculties,particularlyinterms
of internalising behaviours (e.g., anxiety, low mood, with-
drawal, and somatic complaints) and to a lesser extent, exter-
nalising behaviours (aggressive behaviour or deﬁance) [55].
Asthmatic children with behavioural diﬃculties have
been found to be less adherent with asthma medication [56].
8.4. Social Adversity, Ethnicity, and Family Function. Three
relatively small, well-designed studies [21, 42, 56] found no
relationship between adherence and socioeconomic status.
Adherence in these studies was based on either serum drug
levels or EMDs. A number of studies in Western countries
have found adherence to be lower in non-Caucasian partici-
pants [21, 42, 43, 57, 58]. However, minority status is a non-
speciﬁc risk factor and could reﬂect a number of potential
barriers to adherence. A study involving African American
parents from a low-income urban area reported that the
greatest barrier to optimal treatment was parental health
beliefs rather than access to healthcare or ﬁnancial con-
straints [59]. Family dysfunction has been associated with
reduced adherence [12, 21, 56]. Families without strong rou-
tines are lesslikely to ﬁllprescriptions forasthma medication
[60]. Non-adherence is greater in families with high levels of
conﬂict and behavioural problems in their children [56].
8.5. Education, Knowledge and Communication. In order to
be adherent patients require basic information about their
medication, including how and when they are to be taken.
However, numerous studies have failed to correlate asthma
knowledge with the level of adherence [21, 42, 60–63], and
simply providing information does not necessarily improve
adherence [36]. Patients report higher levels of adherence
with medication prescribed by physicians who communicate
well [57, 58] and whose interactions were described as
collaborative rather than authoritarian or generic [51]. In
one study, there was 38% disagreement between parents of
asthmatic children and their doctor about whether preven-
tive medication had been prescribed during a consultation.
Interestingly, discordance was greatest for those parents
who had concerns about or negative perceptions of steroid
medication [64]. In a landmark study, asthma outcomes
were improved when paediatricians were taught to provide
simple messages combined with basic communication and
counseling strategies [65]. Thus, it is important not merely
to educate parents, but to discover and address their speciﬁc
concerns and conﬁrm that you share common goals and
tailor the management plan to the client.
8.6. The Delivery Device. There are limited studies exam-
ining the inﬂuence of the delivery device on adherence.
A breath-activated nebulizer (Halolite) was not found to
improve adherence compared with a standard metered dose
inhaler and spacer [66]. Adherence was not diﬀerent when
two diﬀerent dry powder devices were compared [67]. A
randomised controlled trial which used an EMD to monitor
adherence failed to demonstrate improved adherence by
young children using a novel spacer (Funhaler) that included
an incentive toy (whistle and spinning disk) [68], contrary to
a pilot study that measured adherence using parental report
[69]. It is intuitive to oﬀer patients the opportunity to use
the device they would prefer, but this does not guarantee
increased adherence.
8.7. Frequency of Dosing. T h e r ei sl o w - l e v e le v i d e n c et o
suggest that adherence decreases as the dosing frequency of
prescribed medication increases [24, 70, 71]. Thus, where
possible, the regime should include as few doses as possible.
8.8.TypeofMedication. Adherenceappearstobehigherwith
a once daily oral nonsteroidal asthma medication compared
with an inhaled corticosteroid taken twice daily [72, 73].
ThecombinationofanICSandlong-actingbeta-agonistalso
appears to be associated with superior adherence compared
with ICS alone or both medications in separate inhalers [74–
76]. However, data on combined medications are not based
on studies using EMDs.
8.9. Reminders. The most commonly reported reason
patients give for failing to take medication is simply “forget-
ting” [49, 50, 77]. A randomised controlled study involving
adult asthmatics found a signiﬁcant improvement in adher-
ence in those subjects whose medication was delivered via an
EMD which ﬂashed and beeped to remind them of the need
to take their medication [78].
8.10. Measuring Adherence and Providing Feedback. Several
studies have found increased adherence when data collected
by an EMD were made available to study participants [27,
79–81]. Our group has recently completed a randomised
controlled trial involving 26 children with poorly controlled
asthma over a 4 month period. Average adherence was 21%
higher in those who received feedback on their adherence
at each study visit [82]. Larger studies are required to
demonstrate the clinical eﬃcacy of this strategy.
9. Conclusion
Suboptimal adherence with preventive medication is com-
mon and is associated with signiﬁcant morbidity and
healthcare costs. Non-adherence should be considered in
all children with poorly controlled asthma. Adolescents,
children from chaotic families, and children from socially
disadvantagedgroupsareatincreasedriskofnon-adherence.
Unfortunately, patient report and your own impressions and
knowledge of these risk factors may not help you determine
whether non-adherence is the reason for a child’s poor
asthma control. When prescribing medication, it may be
important to consider the complexity of the regimen in
addition to the eﬃcacy of the intervention. Treatment plans
should be developed collaboratively, and it is important to
explore the patient’s concerns and prejudices. In the future,4 Pulmonary Medicine
EMDs are likely to play a greater role as an aide to remind
patients to take medication, a strategy to motivate patients
to maintain adherence, and a tool to evaluate adherence in
subjects with poor disease control.
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